Cytogel Seeks to Impact Pain Management Market
By Marie Powers
Thursday, April 28, 2011
After nearly a decade of effort, biopharmaceutical development company Cytogel Pharma LLC recently moved its lead candidate a chemically stabilized analogue of endomorphin (EM) 1 designed to treat acute and chronic pain into the clinic.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.